Axsome Therapeutics (AXSM) Other Non-Current Liabilities (2017 - 2026)

Axsome Therapeutics has reported Other Non-Current Liabilities for 7 years, with the latest figure at $73.7 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 18.61% year-over-year to $73.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.7 million (down 18.61% YoY) and the FY2025 annual result came in at $77.5 million, down 15.42% from the prior year.
• Other Non-Current Liabilities fell to $73.7 million in Q1 2026 per AXSM's latest filing, from $77.5 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $91.7 million in Q4 2024 and troughed at $27.4 million in Q3 2022.
• A 5-year average of $61.3 million and a median of $71.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities soared 163.01% in 2024, then dropped 18.61% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $31.1 million in 2022, then soared by 135.69% to $73.3 million in 2023, then rose by 25.08% to $91.7 million in 2024, then decreased by 15.42% to $77.5 million in 2025, then decreased by 4.91% to $73.7 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $73.7 million, $77.5 million, and $89.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.